Smokeless Tobacco - Pouches (not snus): Difference between revisions
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
Please see [[SLT]] page for more details | Please see [[SLT]] page for more details | ||
=Tobacco Free Nicotine Pouches - Studies, Surveys, Papers= | =Tobacco Free Nicotine Pouches - Studies, Surveys, Papers= | ||
===2024: [https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr/ntae131/7693924 The Potential Impact of Oral Nicotine Pouches on Public Health: A Scoping Review]=== | |||
*ONPs appear to be less toxic than cigarettes and deliver comparable nicotine, presenting an alternative for combustible product users, although key data are mainly available from industry-funded studies. Data from independent research is critically needed. | |||
**Citation: Nargiz Travis, Kenneth E Warner, Maciej L Goniewicz, Hayoung Oh, Radhika Ranganathan, Rafael Meza, Jamie Hartmann-Boyce, David T Levy, The Potential Impact of Oral Nicotine Pouches on Public Health: A Scoping Review, Nicotine & Tobacco Research, 2024;, ntae131, https://doi.org/10.1093/ntr/ntae131 | |||
***Acknowledgment: This work was supported by the National Cancer Institute (NCI) and Food and Drug Administration (FDA) grant U54CA229974. All authors declare no conflict of interest. MLG received a research grant from Pfizer and served as a member of the scientific advisory board of Johnson & Johnson. | |||
===2023: [https://www.nature.com/articles/s41415-023-6383-7 Nicotine pouches: a review for the dental team]=== | ===2023: [https://www.nature.com/articles/s41415-023-6383-7 Nicotine pouches: a review for the dental team]=== | ||
*Nicotine pouches are a new product that the dental professional should be aware of, particularly in smokers and ex-smokers. They are likely to have a relatively low-risk profile, similar to other forms of orally administered nicotine; however, the prolonged and regular use may give increased risk of local oral problems. Further research is required. | *Nicotine pouches are a new product that the dental professional should be aware of, particularly in smokers and ex-smokers. They are likely to have a relatively low-risk profile, similar to other forms of orally administered nicotine; however, the prolonged and regular use may give increased risk of local oral problems. Further research is required. | ||
**Citation: M. Jackson, J., Weke, A. & Holliday, R. Nicotine pouches: a review for the dental team. Br Dent J 235, 643–646 (2023). https://doi.org/10.1038/s41415-023-6383-7 | |||
***Acknowledgment: The authors declare no conflicts of interest. (Source of funding?) | |||
===2021: [https://link.springer.com/article/10.1007% | ===2021: [https://link.springer.com/article/10.1007%2Fs13318-021-00742-9 A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette]=== | ||
*NPs (Nicotine Pouches) can provide nicotine in amounts sufficient to replicate cigarette smokers' nicotine uptake following a switch from conventional cigarettes to these potentially less harmful NP products. | *NPs (Nicotine Pouches) can provide nicotine in amounts sufficient to replicate cigarette smokers' nicotine uptake following a switch from conventional cigarettes to these potentially less harmful NP products. | ||
*Citation: McEwan, M., Azzopardi, D., Gale, N. et al. A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette. Eur J Drug Metab Pharmacokinet (2021). doi.org/10.1007/s13318-021-00742-9 | **Citation: McEwan, M., Azzopardi, D., Gale, N. et al. A Randomised Study to Investigate the Nicotine Pharmacokinetics of Oral Nicotine Pouches and a Combustible Cigarette. Eur J Drug Metab Pharmacokinet (2021). doi.org/10.1007/s13318-021-00742-9 | ||
*Acknowledgement: All authors are current employees of British American Tobacco (Investments) Limited except JM who is an employee of RAI Services Company and IMF who is a consultant contracted by British American Tobacco (Investments) Limited. | ***Acknowledgement: All authors are current employees of British American Tobacco (Investments) Limited except JM who is an employee of RAI Services Company and IMF who is a consultant contracted by British American Tobacco (Investments) Limited. | ||
===2020: [https://onlinelibrary.wiley.com/doi/10.1111/ajad.13020 Initial Information on a Novel Nicotine Product]=== | ===2020: [https://onlinelibrary.wiley.com/doi/10.1111/ajad.13020 Initial Information on a Novel Nicotine Product]=== | ||
*Nonusers of tobacco had very little interest in ZYN. Smokeless tobacco users are not only more interested and likely to buy ZYN than other tobacco users, they were the largest group of regular users. | *Nonusers of tobacco had very little interest in ZYN. Smokeless tobacco users are not only more interested and likely to buy ZYN than other tobacco users, they were the largest group of regular users. | ||
*The first assessment of a new nicotine product, ZYN, suggests that current and former tobacco users may perceive ZYN as a reduced‐risk product. ZYN potentially could be used as a smoking/tobacco‐cessation aid based on reasons of current users. | *The first assessment of a new nicotine product, ZYN, suggests that current and former tobacco users may perceive ZYN as a reduced‐risk product. ZYN potentially could be used as a smoking/tobacco‐cessation aid based on reasons of current users. | ||
*[https://sci-hub. | *[https://sci-hub.st/10.1111/ajad.13020 PDF Version] | ||
*Brad Rodu’s Blog: [https://rodutobaccotruth.blogspot.com/2020/05/first-study-of-zyn-novel-consumer.html First Study of ZYN, A Novel Consumer Nicotine Product] | *Brad Rodu’s Blog: [https://rodutobaccotruth.blogspot.com/2020/05/first-study-of-zyn-novel-consumer.html First Study of ZYN, A Novel Consumer Nicotine Product] | ||
**Citation: Plurphanswat, N., Hughes, J. R., Fagerström, K., & Rodu, B. (2020). Initial Information on a Novel Nicotine Product. The American Journal on Addictions. doi:10.1111/ajad.13020 | |||
***Acknowledgment: Drs Plurphanswat and Rodu were supported by unrestricted grants from tobacco manufacturers to the University of Louisville and by the Kentucky Research Challenge Trust Fund. Neither author has any financial or other personal relationship with the sponsors. Dr Hughes has received consulting and speaking fees from several companies that develop or market pharmacological and behavioral treatments for smoking cessation or harm reduction and from several non‐ profit organizations that promote tobacco control. He has recently received consulting fees from Swedish Match, Altria, and Philip Morris International to assist their efforts to develop less‐risky tobacco products. Dr Fagerström has received consulting and speaking fees from many companies that develop or market pharmacological and behavioral treatments for smoking cessation. He currently receives consulting fees from Swedish Match and has received fees in the past from Philip Morris International and BAT to assist their efforts to develop less‐risky tobacco products. | |||
===2020: [https://pubmed.ncbi.nlm.nih.gov/32319528/ Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff]=== | ===2020: [https://pubmed.ncbi.nlm.nih.gov/32319528/ Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff]=== | ||
*The two higher doses of ZYN (6 and 8 mg) deliver nicotine as quickly and to a similar extent as existing smokeless products, with no significant adverse effects. | *The two higher doses of ZYN (6 and 8 mg) deliver nicotine as quickly and to a similar extent as existing smokeless products, with no significant adverse effects. | ||
*Citation: Lunell E, Fagerström K, Hughes J, Pendrill R. Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. Nicotine Tob Res. 2020 Oct 8;22(10):1757-1763. doi: 10.1093/ntr/ntaa068. PMID: 32319528. | *[https://sci-hub.st/10.1093/ntr/ntaa068 PDF Full Version] | ||
**Citation: Lunell E, Fagerström K, Hughes J, Pendrill R. Pharmacokinetic Comparison of a Novel Non-tobacco-Based Nicotine Pouch (ZYN) With Conventional, Tobacco-Based Swedish Snus and American Moist Snuff. Nicotine Tob Res. 2020 Oct 8;22(10):1757-1763. doi: 10.1093/ntr/ntaa068. PMID: 32319528. | |||
***Acknowledgement: The present study was funded by Swedish Match AB, Stockholm, Sweden. The funder developed the protocol and an independent CRO conducted the studies. The funder has provided data, figures and tables, but has in no way approved the manuscript. Dr Lunell has received grants from Swedish Match for a number of clinical trials on nicotine and tobacco products. He has not received any consulting fees from Swedish Match or any other tobacco company. Dr Pendrill is a Research Scientist at Swedish Match. Dr Fagerström has received consulting fees from many companies that develop or market pharmaceutical and behavioral treatments for smoking cessation. He currently receives consulting fees from Swedish Match and has received fees in the past from BAT and PMI to assist their development of less-risky tobacco products. Dr Hughes has received consulting and speaking fees from several companies that develop or market pharmacological and behavioral treatments for smoking cessation or harm reduction and from several non-profit organizations that promote tobacco control. He currently receives consulting fees from the pharmaceutical company Achieve. He also receives fees from the tobacco companies of Swedish Match, Altria and Philip Morris International to assist their efforts to develop less risky tobacco products. | |||
===2020: [https://www.sciencedirect.com/science/article/pii/S0278691520306037 An approach for the extract generation and toxicological assessment of tobacco-free ‘modern’ oral nicotine pouches]=== | ===2020: [https://www.sciencedirect.com/science/article/pii/S0278691520306037 An approach for the extract generation and toxicological assessment of tobacco-free ‘modern’ oral nicotine pouches]=== | ||
*This study demonstrates that tobacco-free nicotine pouches are significantly less biologically active than an equivalent reference Swedish-style snus product. Future product usage studies, pharmacokinetics and clinical studies will provide further data to substantiate the reduced risk potential of tobacco-free modern oral nicotine pouches (MOP). | *This study demonstrates that tobacco-free nicotine pouches are significantly less biologically active than an equivalent reference Swedish-style snus product. Future product usage studies, pharmacokinetics and clinical studies will provide further data to substantiate the reduced risk potential of tobacco-free modern oral nicotine pouches (MOP). | ||
*Citation: Bishop E, East N, Bozhilova S, Santopietro S, Smart D, Taylor M, Meredith S, Baxter A, Breheny D, Thorne D, Gaca M, An approach for the extract generation and toxicological assessment of tobacco-free ‘modern’ oral nicotine pouches, Food and Chemical Toxicology, Volume 145, 2020, 111713, ISSN 0278-6915, doi.org/10.1016/j.fct.2020.111713. | **Citation: Bishop E, East N, Bozhilova S, Santopietro S, Smart D, Taylor M, Meredith S, Baxter A, Breheny D, Thorne D, Gaca M, An approach for the extract generation and toxicological assessment of tobacco-free ‘modern’ oral nicotine pouches, Food and Chemical Toxicology, Volume 145, 2020, 111713, ISSN 0278-6915, doi.org/10.1016/j.fct.2020.111713. | ||
*Acknowledgement: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BAT funded the project and all authors were employees of BAT at the time of the study conduct. LYFT tobacco-free modern oral nicotine pouches are manufactured and supplied by BAT. | ***Acknowledgement: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: BAT funded the project and all authors were employees of BAT at the time of the study conduct. LYFT tobacco-free modern oral nicotine pouches are manufactured and supplied by BAT. | ||
=Articles, Blogs, Videos (Tobacco and Tobacco Free Pouches)= | =Articles, Blogs, Videos (Tobacco and Tobacco Free Pouches)= | ||